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The discovery of sirtuins (SIRT), a family of nicotinamide adenine dinucleotide (NAD)-dependent
deacetylases, has indicated that intracellular NAD level is crucial for the hypertrophic response of
cardiomyocytes. Nicotinamide mononucleotide adenylyltransferase (Nmnat) is a central enzyme
in NAD biosynthesis. Here we revealed that Nmnat2 protein expression and enzyme activity were
down-regulated during cardiac hypertrophy. In neonatal rat cardiomyocytes, overexpression of
Nmnat2 but not its catalytically inactive mutant blocked angiotensin II (Ang II)-induced cardiac
hypertrophy, which was dependent on activation of SIRT6 through maintaining the intracellular
NAD level. Our results suggested that modulation of Nmnat2 activity may be beneﬁcial in cardiac
hypertrophy.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A variety of stress-responsive signaling pathways promote car-
diac hypertrophy, but the mechanisms that link these pathways
are only beginning to be unveiled. The sirtuin (SIRT) family, which
belongs to class III of histone deacetylases (HDACs), is implicated
in the control of critical cellular processes such as differentiation,
proliferation, apoptosis, metabolism and aging [1,2]. In mammals,
there are seven sirtuin family members named SIRT1-7. Recently,
SIRT1, SIRT3, and SIRT7 have been proved to play important roles
in physiological and pathological cardiac growth [3–5]. Our previ-
ous study have also demonstrated that SIRT6 is inactivated during
Ang II-induced cardiac hypertrophy, and increased activity of SIRT6
protects cardiomyocytes from hypertrophic response by suppress-
ing NFjB activation (Supplementary Fig. S1). These ﬁndings conver-
gently suggest that sirtuins may be potential targets for the
prevention and/or treatment of cardiac hypertrophy and heart fail-chemical Societies. Published by E
denine dinucleotide; Nmnat,
ng II, angiotensin II; HDACs,
phoribosyltransferase; AAC,
factor; BNP, brain natriuretic
liupq@mail.sysu.edu.cn (P.-Q.ure. However, the molecular mechanisms underlying sirtuin-medi-
ated cardioprotection and how the functions of sirtuins are
regulated under the circumstance of cardiomyopathy remain to be
clariﬁed.
Nicotinamide adenine dinucleotide (NAD) is a classic coenzyme
with a well-established role in cellular redox reactions. Recently,
several lines of evidence have implicated NAD biochemistry in a
broad range of biological functions [6,7]. It’s now known that the
activity of sirtuins, as NAD-dependent histone deacetylases, is sus-
ceptible to the availability of NAD content, and reduced cellular
levels of NAD attenuate the SIRT deacetylase activity [8]. A recent
study reported that NAD could repress the agonist-induced cardiac
hypertrophy by mediating the activation of SIRT3 but not SIRT1 [9].
Consistently, we found that the deacetylase activity of SIRT6 drops
along with the intracellular NAD level during cardiac hypertrophy,
indicating a close relationship between NAD and SIRT6 in heart
(Supplementary Fig. S1). Therefore, it gives rise to the hypothesis
that artiﬁcial modulation of NAD levels may be used to regulate
the function of sirtuins including SIRT6.
In mammalian cells, the biosynthesis of NAD occurs through
both salvage and de novo pathways [10]. Nicotinamide phosphori-
bosyltransferase (Nampt) is the rate-limiting enzyme for NAD sal-
vage from nicotinamide. Previous study has demonstrated that
overexpression of Nampt signiﬁcantly increased NAD synthesis in
primary cultures cardiomyocytes [11]. However, it was reported
that overexpression of Nampt in cardiomyocytes stimulateslsevier B.V. All rights reserved.
Fig. 1. Tissue distribution and age-dependent expression of Nmnat2 in rats. The mRNA (A) and protein (B) expression of Nmnat2 in different tissues of SD rats were detected
by qRT-PCR and Western blot, respectively. The mRNA expressions of Nmnat isoforms and Nmnat2 protein level in rat hearts at indicated ages were also determined (C and
D). ⁄P < 0.05, ⁄⁄P < 0.01 vs. 1d group, n = 6.
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in vivo [12]. Nmnat is another central enzyme in NAD synthesis
pathway, which catalyzes both de novo and salvage pathways of
NAD synthesis [13]. Up to now, three Nmnat isoforms have been
identiﬁed in mammals which showed differences in subcellular
localization and tissue distribution [14], but very little is known
about the effects of the Nmnat family members on cardiac func-
tion. Among the three Nmnat isoforms, Nmnat2 is reported to be
most sensitive to NAD and can act as a sensor to intracellular
NAD level [13], which might partly explain the facts that high lev-
els of Nmnat2 are detected in the organs with high demand for en-
ergy such as heart, brain and skeletal muscle [14]. Using a positive
screen, we have identiﬁed that the mRNA level of Nmnat2, but not
Nmnat1 and Nmnat3, is signiﬁcantly upregulated in response to
hypertrophic stimulation. However, to our best knowledge, there
are no investigations on the potential roles of Nmnat2 in cardiac
hypertrophy.
In this study, by using gain- and loss-of-function approaches in
cardiomyocytes we show that Nmnat2 is a negative regulator of
cardiac hypertrophy. Our results also reveal that the anti-hypertro-
phic effect of Nmnat2 is dependent on its NAD synthesis activity
and is possibly mediated via activation of SIRT6. These ﬁndings
give the ﬁrst look into the relationship between Nmnat2 and
SIRT6-mediated cardioprotection, and may provide a potentially
novel strategy against cardiac hypertrophy by modulating Nmnat2.
2. Materials and methods
SD rats (male, weighing 180–200 g, SPF grade, certiﬁcation No.
0067950) were supplied by the Experimental Animal Center of
Sun Yat-Sen University (Guangzhou, China). Pressure overload
was induced by abdominal aortic constriction (AAC) according to
procedure reported by others [15]. Primary cultures of neonatal
rat cardiomyocytes were prepared as we previously described
[16]. The EGFP-Nmnat2 (Nmnat2) and the catalytically inactivemutant (H24D) plasmids were purchased from LAND Company.
Plasmids were transfected into cells using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol.
Additional materials and methods including echocardiography
and morphometric measures, quantitative real-time polymerase
chain reaction (qRT-PCR), Western blot and immunoprecipitation,
SIRT6 histone deacetylase activity assay, NAD determination, mea-
surement of cell surface area, immunoﬂuorescence assay, Nmnat2
enzyme activity assay and RNA interference are listed in Supple-
mentary data. Data are presented as mean ± S.E. Statistical analyses
between two groups were performed by unpaired Student’s t-test.
Differences among groups were tested by one-way analysis of var-
iance (ANOVA) with Tukey’s post hoc test. In all cases, differences
were considered statistically signiﬁcant with P < 0.05.
3. Results
3.1. Tissue distribution and age-dependent expression of Nmnat2 in
rats
As shown in Fig. 1A and B, Nmnat2 was highly expressed in
liver, heart, brain and muscle, while it could hardly be detected
in spleen, lung, kidney and testis. We further investigated the
expression of Nmnat isoforms in hearts of rats at indicated ages.
The results showed that the mRNA and protein expression of
Nmnat2 (Fig. 1C and D) was increased in an age-dependent man-
ner, which reached peak at 12 weeks (P < 0.01, compared with 1d
group). In contrast, the expression of Nmnat1 and Nmnat3 showed
no signiﬁcant age-related changes.
3.2. Expression and NAD synthase activity of Nmnat2 in neonatal rat
cardiomyocytes treated with Ang II
Ang II is an well-established neurohumoral factor that can stim-
ulate cardiac hypertrophy [17]. As shown in Fig. 2A, the mRNA
Fig. 2. The protein expression and NAD synthase activity of Nmnat2 was decreased in neonatal rat cardiomyocytes treated with Ang II. (A) The mRNA levels of Nmnat
isoforms were determined by qRT-PCR after treatment with 100 nM Ang II for 24 h. The time and concentration-dependent effect of Ang II on Nmnat2 mRNA and protein
expression was detected by qRT-PCR (B and C) and Western blot (D and E). (F) The Nmnat2 enzyme activity in cardiomyocytes treated with 100 nM AngII. ⁄P < 0.05, ⁄⁄P < 0.01
vs. control, n = 5.
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enhanced after treatment with 100 nM Ang II (P < 0.05, compared
with control). Furthermore, the Nmnat2 mRNA expression in-
creased in a dose and time dependent manner responding to Ang
II stimulation (Fig. 2B and C). However, Ang II downregulated
Nmnat2 protein expression in a dose and time dependent manner
(Fig. 2D and E), and Nmnat2 NAD synthase activity dropped grad-
ually after the treatment with 100 nM Ang II (Fig. 2F).
3.3. Expression and NAD synthase activity of Nmnat2 in AAC rats
Abdominal aortic constriction surgery was performed to produce
pressure overload hypertrophy in rats. At 8 weeks after surgery, the
hearts of AAC rats were obviously larger than that of sham-operated
animals (sham) and presented with typical hypertrophic changes as
demonstrated by HE staining (Supplementary Fig. S2A–C). The echo-
cardiography revealed that IVSd, IVSs, LVPWd and LVPWswere signif-
icantly increased, whereas LVIDs was decreased after AAC
(Supplementary Fig. S2D and Table S2). The heart weight to bodyweight (HW/BW) ratio and left ventricle weight to body weight
(LVW/BW) ratio were both increased in AAC rats comparing with
sham-operated animals (Supplementary Fig. S2E and Table S3). And
the expression of hypertrophy marker genes including ANF, BNP and
b-MHCmRNAwas signiﬁcantly increased in AAC rats (Supplementary
Fig. S2F). These results convergently suggested the successful induc-
tion of cardiac hypertrophy by AAC surgery. In addition, as shown in
Fig. 3A and B, both protein expression and enzyme activity of Nmnat2
were signiﬁcantly downregulated (45.8 ± 5.76% and 51.2 ± 4.96%,
respectively, P < 0.01, compared with Sham group) after 8 weeks of
pressure overload induced by AAC.
3.4. Nmnat2 protected cardiomyocytes from Ang II-induced
hypertrophy in neonatal rat cardiomyocytes
To investigate the potential effect of Nmnat2 on cardiac hyper-
trophy, neonatal rat cardiomyocytes were transfectedwith Nmnat2
or H24D, which lacked NAD synthase activity (Fig. 4A and B). Subse-
quently, the cells were treated with 100 nM Ang II for 24 h, and
Fig. 3. Nmnat2 protein expression was downregulated in AAC rats. (A) The protein
levels of Nmnat2 were detected by Western blot. (B) Nmnat2 enzyme activity in
AAC and sham rats. ⁄P < 0.05 vs. sham, n = 8.
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sults showed that after Ang II stimulation, the Nmnat2 and H24D
protein levels were higher in Nmnat2-tranfected cardiomyocytes
than in cells without transfection. It indicated that overexpression
of Nmnat2 and H24D could signiﬁcantly attenuate Ang II-induced
the downregulation of Nmnat2 protein level (Supplementary
Fig. S5). Then, the cellular hypertrophy response was indicated by
increase in cell surface area and activation of fetal gene expression.
As shown in Fig. 4C and D, overexpression of Nmnat2, but not the
H24D, could signiﬁcantly attenuate Ang II-induced hypertrophic
response.
After that, we took the approach of RNA interference to knock
down the endogenous Nmnat2 in cardiomyocytes. Quantitative
RT-PCR and Western blot was performed to evaluate the effect of
three independent siRNAs, marked si001, si002, and si003, respec-
tively. As shown in Fig. 5A and B, si003 reduced the mRNA and pro-
tein expression of Nmnat2 by 83% and 81%, respectively (P < 0.01,
compared with control), and did not interfere with Nmnat1 and
Nmnat3 (Fig. 5C), exhibiting potential efﬁcacy and selectivity for
Nmnat2 silence. Therefore, it was used in the following experi-
ments. The cell surface area and mRNA levels of ANF, BNP and
b-MHC were measured after transfection. The results revealed that
the downregulation of Nmnat2 by siRNA003 could mimic the
effects of Ang II as indicated by increased cell surface area as well
as high expression of hypertrophic biomarkers (Fig. 5D and E).
3.5. The anti-hypertrophic effect of Nmnat2 was dependent on
activation of SIRT6, but not SIRT1
As shown in Fig. 6A, overexpression of Nmnat2markedly increased
cellular level of NAD (1.52-fold, P < 0.01, comparedwith vector group).
Ang II treatment and transfectionwith vector or H24D signiﬁcantly re-
duced the NAD level in a time-dependent manner. In contrast, aftertransfection with, no signiﬁcant decrease of NAD content was ob-
served following Ang II treatment (Fig. 6B). Among all seven sirtuins,
SIRT6 mRNA expression was increased 2.5-fold in response to Ang II
stimulation, and SIRT1 also showed slight increase (Fig. 6C). The pro-
tein expression and enzyme activity of SIRT6 were obviously elevated
after transfection with Nmnat2 (Fig. 6D and E). Furthermore, confocal
immunoﬂuorescence microscopy revealed that SIRT6 was predomi-
nantly localized in the nucleus, while Nmnat2 was localized in the
cytoplasm (Fig. 6F), suggesting that therewas no direct interaction be-
tween Nmnat2 and SIRT6. As shown in Fig. 6G and H, overexpression
of Nmnat2, but not H24D, could increase the SIRT6 protein expression
and enzyme activity, and similar effects were observed with NAD
supplement.
However, in cells transfected with si003, knockdown of Nmnat2
signiﬁcantly decreased NAD content, SIRT6 protein expression and
enzyme activity (Fig. 7A–C). As shown in Fig. 7D, when SIRT6 but
not SIRT1 was knocked down, cardiomyocytes with Nmnat2 over-
expression showed a signiﬁcantly increase in hypertrophic re-
sponse as determined by the expression of cardiac fetal gene. It
suggested that Nmnat2 overexpression was unable to block Ang
II-induced cardiac hypertrophy without the participation of SIRT6.
In addition, SIRT6 overexpression could attenuate hypertrophic re-
sponses induced by Nmnat2 knockdown (Supplementary Fig. S6) as
indicated by decreased expression of hypertrophic biomarkers as
well as cell-surface area.
3.6. Proteasome participated in Ang II-induced Nmnat2 expression in
cardiomyocytes
Cardiomyocytes were pretreated with 1 lM proteasome inhib-
itor MG132 for 1 h followed by stimulation with 100 nM Ang II.
In Fig. 8A, Nmnat2 protein level dropped after Ang II stimulation
for 48 h, which could be attenuated by MG132 pretreatment.
And MG132 alone could signiﬁcantly upregulate Nmnat2 protein
expression as compared with control group. However, as shown
in Fig. 8B, Nmnat2 mRNA expression increased after Ang II treat-
ment. MG132 pretreatment could block this Ang II-induced effect,
andMG132 alone did not affect the mRNA expression of Nmnat2 as
compared with control.4. Discussion
Nmnat catalyzes the last step in the biosynthesis of NAD. In
contrast to Nmnat1 and Nmnat3, which appear to be almost ubiq-
uitously expressed, it was reported that Nmnat2 mRNA mainly ex-
pressed in high energy consumption organs including brain, heart
and skeletal muscle [14], showing a close relationship between
Nmnat2 and energy metabolism. Here, we revealed that Nmnat2
protein was highly expressed in brain, heart, liver and skeletal
muscle of SD rats, while there was nearly no Nmnat2 detected in
kidney, lung, spleen and testis (Fig. 1A). Moreover, the expression
of Nmnat2 signiﬁcantly increased with age in rat hearts (Fig. 1B
and C). It suggests that the upregulation of Nmnat2 during aging
may be a compensatory mechanism to maintain the cardiac level
of NAD.
Recently, it has been recognized that maintaining intracellular
levels of NAD is essential for many crucial cell processes, including
energy metabolism, intracellular Ca2+ regulation and the activity of
sirtuins [11,18,19]. Moreover, researchers have proved that patho-
logic cardiac hypertrophy is associated with depletion of cellular
NAD, and NAD treatment can block the agonist-triggered cardiac
hypertrophic response [9]. Thus, enzymes involved in NAD biosyn-
thetic pathways have drawn increased attentions. Nampt catalyzes
the ﬁrst reversible step in NAD biosynthesis and nicotinamide
(NAM) salvage [20]. It has been demonstrated that upregulation
Fig. 4. Nmnat2 blocked cardiomyocyte hypertrophy through its NAD synthesis activity. The neonatal rat cardiomyocytes were transfected with Nmnat2 or catalytically
inactive mutant H24D. The protein expression (A) and NAD synthesis activity (B) of Nmnat2 were detected. The cells were further treated with 100 nM Ang II for 24 h. The cell
surface area (C) and mRNA levels of ANF, BNP and b-MHC (D) were measured respectively. ⁄P < 0.05 vs. control, #P < 0.05 vs. Ang II treatment, n = 5.
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dent SIRT1 activity [12]. However, it remains necessary to investi-
gate the potential effects of other NAD synthases on cellular NAD
level and NAD-dependent pathways related to cardiomyopathy.
In this study, we screened the mRNA expressions of all Nmnat iso-
forms in Ang II-induced cardiomyocyte hypertrophy, and found the
change of Nmnat2 was most signiﬁcant (Fig. 2A). Our results also
demonstrated that overexpression of wide-type Nmnat2, but not
its catalytically inactive mutant, could block Ang II-induced cardiac
hypertrophy (Fig. 4). Intriguingly, we showed that overexpression
of Nmnat2 in cardiomyocytes signiﬁcantly increased NAD content
and upregulated the mRNA and protein levels of SIRT6 (Fig. 6A, C
and D). Recently, the modulatory effect of NAD on expression pro-
ﬁles of sirtuins has begun to be realized. It was reported that themRNA level of SIRT1 could be increased by NAD directly [21]. Pillai
et al. also revealed that the protein level of SIRT3 was markedly
elevated after NAD treatment [9]. Although the mechanism under-
lying remains unclariﬁed, it has been suggested that PPARa may
act as a transcriptional factor for SIRT1, which is activated by
NAD and subsequently promotes SIRT1 expression [21]. Certainly,
whether similar or different signaling pathways were involved in
the regulation of SIRT6 still require further investigation.
The roles of sirtuins, a family of NAD-dependent histone deacet-
ylases, in aging-related diseases have been intensively explored in
the last decade [22]. The best-characterized sirtuin, SIRT1, has been
indicated to protect cardiomyocytes from oxidative stress-medi-
ated cell death and retard certain cardiac degenerative changes
associated with aging [23,24]. Researchers have also revealed that
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models of cardiovascular diseases [25]. However, although moder-
ate overexpression of SIRT1 protected against oxidative stress and
age-dependent cardiac dysfunction, higher expression levels of
SIRT1 could lead to apoptosis and hypertrophy and decrease car-
diac function, suggesting a rather narrow window of optimal SIRT1
activity [26]. Moreover, recent study showed that SIRT1 activation
was not involved in the regulation of NAD for cardiac hypertrophy
[9]. Here, by using RNA interference, we revealed that SIRT6, but
not SIRT1, participated in the anti-hypertrophic signals of Nmnat2
overexpression (Fig. 7D). This result is consistent with our previous
ﬁnding that knockdown of SIRT6 in primary cardiomyocytes led to
obvious cellular hypertrophy (unpublished data).
In this study, the discrepancy between mRNA and protein levels
of Nmnat2 in response to hypertrophic stimuli promoted us to
explore whether protein degradation pathway participated in the
regulation of Nmnat2 expression. It is well known that the ubiqui-
tin–proteasome system plays a pivotal role in the degradation of
short-lived, regulatory proteins important for a variety of basic
cellular processes, including regulation of the cell cycle, modulation
of cell-surface receptors and ion channels, aswell as antigen presen-
tation [27,28]. The crucial role of this system in human disease is
obvious, because its dysregulation will result in inappropriateFig. 5. Nmnat2 knockdown mimicked the hypertrophic responses in neonatal rat cardio
si003) and negative control (Neg). The mRNA level (A) and protein expression (B) of Nm
transfection with Neg or si003. (D and E) The cell surface area and mRNA levels of ANF, BN
or submitted to Nmnat2 knockdown by si003. ⁄P < 0.05 vs. control, n = 5.degradation of proteins and ensure pathological consequences
[29]. And aberrations in the ubiquitin–proteasome system have
been implicated in pressure overload-induced cardiac hypertrophy
[30]. By using MG-132, a speciﬁc protease inhibitor, we found that
activation of proteasome was required for Ang II induced Nmnat2
expression, which may also explain that inhibition of proteasomal
degradation increases SIRT6 levels [31]. In agreement with our re-
sults, Gilley et al. have also shown that Nmnat2 is the most labile
Nmnat isoform that is degraded by the proteasome in HEK cells
[32]. Our study gives the extra support to the possibility of using
proteasome inhibitors against cardiac hypertrophy.
Another noteworthy ﬁnding of the current study is that expres-
sion at the transcript level does not always correspond to expression
at the protein level, which highlights the complexity inherent in
transcriptional and translational regulation. In the current study,
our data showed that the Nmnat2 protein expression dropped in
cardiomyocytes after Ang II stimulation, while its mRNA level was
increased simultaneously. This unexpected ﬁnding may suggest
the existence of an autoregulatory feedback loop to maintain
Nmnat2 protein and mRNA homeostasis. In fact, a number of pro-
teins have been reported to act as a regulator of its own expression
at the transcript level [33–35]. For instance, PARP-1, by binding to
BUR-related structures in its promoter, down-regulated its ownmyocytes. Cells were transfected with siRNAs for Nmnat2 (marked si001, si002 and
nat2 were detected respectively. (C) The mRNA expression of Nmnat isoforms after
P and b-MHC were measured in cardiomyocytes treated with 100 nM Ang II for 24 h
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nous protein is efﬁciently and continuously kept in check through
the downregulation of transcript levels by the protein molecules
present in excess. Self-regulation of expression becomes particu-
larly important for proteins whose abundance results in cellular
toxicity. Thus, it may be speculated that a similar mechanism is in-
volved in the control of Nmnat2 level and subsequent NAD synthe-
sis. Although Nmnat2 locating mainly in cytoplasm is unable to
regulate its own transcription by directly acting as an mRNA pro-
cessing factor, there remains a possibility that overexpressed
Nmnat2 protein, in some unknown or indirect way, suppress theFig. 6. Overexpression of Nmnat2 increased SIRT6 expression and deacetylase activity in
content (A) was measured. The cells were further treated with 100 nM Ang II. The intrac
indicated time points. ⁄P < 0.05 vs. vector, n = 5. (D) Representative immunoreactive ban
was measured in cardiomyocytes transfected with Nmnat2. ⁄P < 0.05 and ⁄⁄P < 0.01 vs. co
detected by confocal immunoﬂuorescence microscopy. DAPI was used to mark the nucle
in cardiomyocytes transfected with Nmnat2, H24D or treated with 50 lM NAD. ⁄P < 0.0mRNA expression of itself. Conversely, Ang II treatment leads to de-
crease in Nmnat2 protein, thereby relieving the repressed gene
transcription and resulting in elevated Nmnat2 mRNA level. MG-
132 blocks the degeneration of Nmnat2 protein induced by Ang II,
so that Nmnat2mRNA expression may be remained at a basal level.
Further studies concerning this point are necessarily warranted.
In conclusion, the data presented here give the ﬁrst evidence
that Nmnat2 protects cardiomyocytes from Ang II-induced hyper-
trophy, which may involve the activation of SIRT6. It raises the pos-
sibility that drugs modulating Nmnat2 activity may be utilized to
treat or prevent cardiac hypertrophy.neonatal rat cardiomyocytes. Cells were transfected with Nmnat2 for 24 h. The NAD
ellular NAD levels (B) and mRNA changes of all seven sirtuins (C) were measured at
ds of SIRT1 and SIRT6 after Nmnat2 transfection. (E) The SIRT6 deacetylase activity
ntrol, n = 5. (F) The intracellular distribution of Nmnat2 (red) and SIRT6 (green) were
i. (G and H) The protein expression and deacetylase activity of SIRT6 were measured
5 vs. control, #P < 0.05 vs. Nmnat2 group and $P < 0.05 vs. H24D group, n = 5.
Fig. 7. Nmnat2 knockdown decreased NAD content, SIRT6 protein expression and enzyme activity. Neonatal rat cardiomyocytes were transfected with si003 and negative
control (Neg) for 24 h. The NAD levels (A), protein expression and deacetylase activity of SIRT6 (B and C) were measured. (D) Cardiomyocytes overexpressed with Nmnat2
after transfection with siSIRT6 or siSIRT1 were treated with Ang II for 24 h. The mRNA levels of hypertrophic biomarkers were measured by qRT-PCR. ⁄P < 0.05 vs. control,
#P < 0.05 vs. Ang II treatment and $P < 0.05 vs. Nmnat2 overexpression plus Ang II treatment.
Fig. 8. Proteasome participated in Ang II-induced Nmnat expression. Neonatal rat cardiomyocytes were pretreated with 1 lM proteasome inhibitor MG132 for 1 h followed
by stimulation with 100 nM Ang II. The protein and mRNA expressions of Nmnat2 were detected by Western blot (A) and qRT-PCR (B). ⁄P < 0.05 vs. control and #P < 0.05 vs.
Ang II treatment, n = 5.
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